Filtered By:
Condition: Bleeding
Management: Insurance

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 143 results found since Jan 2013.

Effectiveness and Safety of Rivaroxaban by General Practitioners 　- A Multicenter, Prospective Study in Japanese Patients With Non-Valvular Atrial Fibrillation (GENERAL)
CONCLUSIONS: The low incidence of adverse events, including stroke/SE and bleeding, in patients prescribed rivaroxaban by general practitioners supports its use as a safe and efficacious treatment in the standard clinical care of high-risk patient populations.PMID:33814525 | DOI:10.1253/circj.CJ-20-1244
Source: Circulation Journal - April 5, 2021 Category: Cardiology Authors: Kengo Kusano Nobuyoshi Sugishita Masaharu Akao Hikari Tsuji Kunihiko Matsui Shinya Hiramitsu Yutaka Hatori Hironori Odakura Hiroyuki Kamada Koji Miyamoto Hisao Ogawa Source Type: research

Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
CONCLUSIONS: These results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity in a commercially-insured US population.PMID:33733969 | DOI:10.1080/03007995.2021.1901223
Source: Current Medical Research and Opinion - March 18, 2021 Category: Research Authors: Jeffrey S Berger Fran çois Laliberté Akshay Kharat Dominique Lejeune Kenneth Todd Moore Young Jung Patrick Lefebvre Veronica Ashton Source Type: research

Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation
ConclusionsFor patients whose HAS-BLED scores increased to  ≥ 3, the continuation of OACs was associated with better clinical outcomes. An increased HAS-BLED score in anticoagulated AF patients may not be the only reason to withhold OACs, but reminds physicians to correct modifiable bleeding risk factors and follow up patients more closely.Graphical abstractAssociations between Continuation or Discontinuation of Oral Anticoagulants and Risks of Clinical Outcomes after HAS-BLED Scores IncreasedAF atrial fibrillation;aHR adjusted hazard ratio;ICH intra-cranial hemorrhage;OACs oral anticoagulants
Source: Clinical Research in Cardiology - March 11, 2021 Category: Cardiology Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients with Atrial Fibrillation and Valvular Heart Disease.
CONCLUSIONS: NOACs had a comparable risk of ischemic stroke and bleeding in patients with AF and VHD, and reduced the risk of venous thromboembolism, intracranial hemorrhage, and mortality, compared to warfarin. Therefore, NOAC is an effective and safe alternative to warfarin in these patients. PMID: 33538623 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 6, 2021 Category: Research Tags: Curr Med Res Opin Source Type: research

Use of durable left ventricular assist devices for high-risk patients: Korean experience before insurance coverage.
Conclusions: All patients who received LVADs before insurance coverage had contraindications for HT. The overall outcomes were comparable with those reported in the international registry. PMID: 33447412 [PubMed]
Source: Journal of Thoracic Disease - January 17, 2021 Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research

Age-dependent anticoagulant therapy for atrial fibrillation patients with intermediate risk of ischemic stroke: A nationwide population-based study.
CONCLUSIONS: Age is an important determinant of ischemic stroke and composite outcome in intermediate-risk AF patients. The benefit of OAC therapy for these AF patients appears to have an age threshold (age ≥ 55 years). PMID: 33307565 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2020 Category: Hematology Authors: Choi SY, Kim MHH, Lee KM, Cho YR, Park JS, Yun SC, Lip GY Tags: Thromb Haemost Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis
ConclusionsDOACs did not provide benefit over warfarin regarding effectiveness and safety in AF patients undergoing dialysis. The use of OAC was not associated with a lower risk of IS/SE in ESRD AF patients when compared to those without OAC use.
Source: Cardiovascular Drugs and Therapy - November 19, 2020 Category: Cardiology Source Type: research

Real-World Bleeding and Ischemic Events in Asian Patients on P2Y12-Inhibitors After Percutaneous Coronary Intervention: A National Claims Data Analysis
ConclusionsCDAPT was associated with clinical outcomes that were more favorable than those in TDAPT and comparable to those in PDAPT and drug persistence and adherence that were higher than in TDAPT or PDAPT. Clopidogrel may remain a viable first option for post-PCI DAPT in East Asian patients with a low thrombotic risk and a high bleeding tendency.
Source: Advances in Therapy - November 11, 2020 Category: Drugs & Pharmacology Source Type: research

Trends and outcomes of device-related 30-day readmissions after left ventricular assist device implantation.
CONCLUSION: Over one-fourth of LVAD recipients have 30-day readmissions, with most of them occurring within 15 days. Most frequent cause of readmission was gastrointestinal bleeding, which was associated with the lowest in-hospital mortality among other complications. PMID: 33039191 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - October 7, 2020 Category: Internal Medicine Authors: Briasoulis A, Ueyama H, Kuno T, Asleh R, Alvarez P, Malik AH Tags: Eur J Intern Med Source Type: research

Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles
ConclusionsFrom a US private payer ’s perspective, dabigatran appears cost effective compared with other anticoagulants. This study indicated risk stratification especially considering both stroke and bleed risk simultaneously is important not only in clinical practice but also in health technology assessment exercises among patien ts with atrial fibrillation.
Source: PharmacoEconomics - September 13, 2020 Category: Health Management Source Type: research

Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding.
CONCLUSION: When NSAIDs or SSRIs are required for NOAC users with AF, physicians need to monitor bleeding events and consider the use of PPIs, especially for combined use of both drugs or when initiating NOACs treatment. PMID: 32882758 [PubMed - in process]
Source: Yonsei Medical Journal - August 31, 2020 Category: Universities & Medical Training Authors: Lee MT, Park KY, Kim MS, You SH, Kang YJ, Jung SY Tags: Yonsei Med J Source Type: research